Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Nuo Therapeutics, Inc. (AURX)
Price$1.21Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2013
2014
2015
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3M | $1.4M | $608,525 | $112,250 | $0 | $0 | $146,177 | $1.4M | $721,045 | $472,445 | $11.5M | $7.8M | $11.6M | $10.6M | $7.2M | $3.9M |
| Gross profit | $2.2M | $1.1M | $482,433 | $93,036 | $0 | $0 | $31,563 | $1.2M | −$369,997 | −$256,605 | $3.5M | $991,191 | $3.1M | $6.6M | $4.5M | $2.3M |
| Gross margin | 66.94% | 77.82% | 79.28% | 82.88% | — | — | 21.59% | 88.11% | −51.31% | −54.31% | 30.79% | 12.77% | 26.95% | 62.95% | 62.37% | 58.76% |
| Research & development | — | — | — | — | $0 | $0 | $181,185 | $576,192 | $1.3M | $1.0M | $2.6M | $4.0M | $3.8M | $3.4M | $98,148 | $415,633 |
| Operating expenses | $4.7M | $3.5M | $3.7M | $3.4M | $90,670 | $378,059 | $1.0M | $2.7M | $15.2M | $5.2M | $44.9M | $24.4M | $21.2M | $19.5M | $8.0M | $7.7M |
| Operating income | −$2.5M | −$2.5M | −$3.2M | −$3.3M | −$90,670 | −$378,059 | −$969,198 | −$1.5M | −$15.5M | −$5.5M | −$41.3M | −$23.4M | −$18.1M | −$12.9M | −$3.5M | −$5.4M |
| Operating margin | −75.95% | −180.04% | −520.65% | −2,958.21% | — | — | −663.03% | −109.78% | −2,154.40% | −1,155.26% | −358.96% | −301.35% | −156.38% | −122.06% | −48.49% | −138.15% |
| EBITDA | −$2.4M | −$2.4M | −$3.2M | −$3.3M | −$90,670 | −$378,059 | −$879,339 | −$1.4M | −$14.4M | −$4.6M | −$40.6M | −$22.8M | −$17.0M | −$11.7M | −$2.9M | −$5.0M |
| EBITDA margin | −73.37% | −178.35% | −518.13% | −2,952.13% | — | — | −601.56% | −102.33% | −1,999.92% | −978.27% | −352.52% | −293.45% | −146.94% | −110.90% | −39.78% | −126.89% |
| Net income | −$2.5M | −$2.3M | −$3.2M | −$3.2M | −$90,670 | −$90,870 | −$1.2M | −$1.5M | −$15.0M | −$5.7M | −$52.8M | −$18.9M | −$20.2M | −$19.8M | −$3.5M | −$6.8M |
| Net profit margin | −75.82% | −170.21% | −521.17% | −2,825.60% | — | — | −817.43% | −112.49% | −2,077.36% | −1,205.56% | −458.76% | −243.28% | −174.99% | −187.41% | −48.44% | −174.30% |
| Basic EPSper basic share | -$0.05 | -$0.05 | -$0.08 | -$0.08 | -$0.03 | $0.30 | -$0.05 | -$0.07 | -$1.02 | -$0.58 | -$0.42 | -$0.16 | -$0.20 | -$0.24 | -$0.08 | -$0.23 |
| Diluted EPSper diluted share | -$0.05 | -$0.05 | -$0.08 | -$0.08 | -$0.03 | $0.27 | -$0.05 | -$0.07 | -$1.02 | -$0.58 | -$0.42 | -$0.16 | -$0.20 | -$0.24 | -$0.08 | -$0.23 |
Owners
Reported shareholders
≈23.90%of listed shares
SHEEDY CHARLES E11.57M shares · Jul 30, 2025
View holders
| Holder | % owned |
|---|---|
SHEEDY CHARLES E | ≈23.90%11.57M shares |
Pittman Scott M. | ≈11.15%5.4M shares |
JORDEN DAVID EMERSON | ≈4.31%2.09M shares |
CLAUSEN PETER | ≈1.60%773.53K shares |
WINZER C ERIC | ≈0.36%172.65K shares |
Mintz Paul | ≈0.22%108.29K shares |
Ancora Advisors LLC | <0.01%4.7K shares |
Percentages use 48.42M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 28, 2025Form 4 | JORDEN DAVID EMERSONCEO/CFO | SellCommon Stock | 200.0K | $1.50 | $300.0K | 1.95M |
| Jul 30, 2025Form 4 | SHEEDY CHARLES ETenPercentOwner | BuyCommon Stock | 133.3K | $1.50 | $200.0K | 11.57M |
| Sep 18, 2024Form 4 | SHEEDY CHARLES ETenPercentOwner | BuyCommon Stock | 125.0K | $0.75 | $93.8K | 11.44M |